Plasma exchange and infliximab as a third-line therapy for refractory infantile Kawasaki disease
{{output}}
Background: The treatment for Kawasaki disease (KD) patients refractory to intravenous immunoglobulin (IVIG) therapy is still controversial, and the efficacy of plasma exchange (PE) and infliximab (IFX) therapy for infantile KD i... ...
